You have seen the headlines: a biotech signs a deal “worth up to two billion dollars.” Then you look at the company’s financials and find they received seventy million. Both numbers are true, and understanding why is essential to reading biotech deals intelligently. Deal headlines quote the theoretical maximum if everything succeeds, while the actual money is split across an upfront payment, milestones that may never be earned, and royalties on sales that may never happen. Here is how it really works.
The three components
Almost every biotech licensing deal is built from the same three pieces.
- The upfront payment is cash paid at signing. It is the only money that is certain, and it is therefore the most meaningful single number in any deal. It signals how much conviction the partner has, and it is the money the licensor can actually count on.
- Milestone payments are contingent, paid when specified events occur, entering a trial phase, achieving a regulatory approval, hitting a sales threshold. They are typically split into development milestones (tied to clinical and regulatory progress) and commercial milestones (tied to sales levels once marketed).
- Royalties are a percentage of net sales, paid for as long as the deal specifies, which is where the truly large money lives if a drug becomes a commercial success.
The headline number sums all of these at their maximum, which is why the industry wryly calls them “biobucks.”
Why the headline is misleading
The theoretical maximum assumes the drug clears every clinical hurdle, wins approval, and reaches peak commercial milestones, an outcome that is genuinely unlikely given how most drug candidates fail. Because commercial milestones are usually the largest and require blockbuster-level sales, the biggest chunks of a headline number are frequently the least likely to be paid. This is not deception, both parties understand it, but it means that reading a deal’s value from its headline is naive. The sophisticated read starts with the upfront, then asks how probable each milestone genuinely is.
Why deals are structured this way
The structure exists to share risk. The licensee is buying an asset that will probably fail, so they limit their guaranteed exposure through a modest upfront and tie the rest of the payment to success. The licensor accepts less certain cash in exchange for a share of the upside if the drug works. A deal heavy on milestones and royalties reflects greater uncertainty or a licensee unwilling to bet big upfront; a large upfront reflects real conviction and a more de-risked asset. This is why upfront size tracks so closely with the stage of the asset: later-stage, de-risked programs command far larger upfronts, which is one of the strongest arguments for advancing an asset before licensing it.
How to read a deal properly
Look past the headline at four things. First, the upfront, which is the certain money and the truest signal of the partner’s conviction. Second, the structure of the milestones: are they front-loaded and achievable, or back-loaded behind commercial thresholds that require a blockbuster? Development milestones tied to near-term events are worth far more in expectation than sales milestones requiring billions in revenue. Third, the royalty rate and its terms, including whether it tiers upward with sales and how long it runs, since royalties on a successful drug can dwarf everything else. Fourth, the other terms, the territory, the retained rights, what happens if the partner deprioritizes the program, and whether rights revert to you.
What this means for founders and investors
For a company out-licensing an asset, the practical lessons are clear: negotiate the upfront hard, because it is the only certain money; structure milestones so meaningful payments arrive at events you can realistically reach; pay close attention to royalty terms, since that is where the real long-term value sits; and protect yourself with reversion rights if the partner stalls the program. For an investor reading a deal announcement, discount the headline heavily, look at the upfront as the real signal, and assess how probable the milestones actually are. Two deals with identical headline numbers can be worth wildly different amounts, and the difference is entirely in the structure.
The bottom line
Biotech deal headlines are theoretical maximums that assume everything goes right, which it usually does not. The upfront is the certain money and the clearest signal of conviction, milestones are contingent and often back-loaded behind improbable commercial thresholds, and royalties are where the transformational value lives if a drug actually succeeds. Read deals by structure rather than headline, negotiate structure as hard as size, and you will understand what a transaction is genuinely worth, which is a skill that separates sophisticated participants from those reading press releases.
Diligence on the milestones themselves
Because milestones carry so much of a deal’s nominal value, it is worth learning to assess them properly rather than accepting them at face value, and a few questions do most of the work. First, what triggers each milestone, exactly? Vague or subjective triggers are a source of dispute and can leave you arguing about whether a payment is owed. Precise, objective, verifiable events are far better for both parties. Second, how probable is each milestone, honestly? A development milestone tied to starting a trial you are already planning is nearly certain; a commercial milestone requiring several billion dollars in annual sales is, for most drugs, close to fantasy, and treating those two as equivalent components of a headline number is exactly the error the headline invites. Third, who controls whether the milestone happens? This matters enormously: if your partner controls the development decisions that trigger your milestones, and they deprioritize the program, your milestones may never arrive regardless of the science. This is why diligence obligations, requiring the partner to use defined efforts to develop and commercialize the asset, and reversion rights if they do not, are among the most valuable protections in any licensing agreement. Fourth, what happens on a change of control? If your partner is acquired and the acquirer has different priorities, your program’s fate and your milestones can change entirely. Asking these questions turns a milestone schedule from a list of hopeful numbers into an assessable set of probabilities and protections, which is exactly how sophisticated parties on both sides of a deal actually think about it.
The bottom line, restated
Read biotech deals by structure, not headline. The upfront is the certain money and the truest signal of conviction; milestones are probabilities dressed as numbers; royalties are where transformational value lives if a drug actually succeeds; and the terms governing diligence, control, and reversion determine whether any of it materializes. Negotiate structure as hard as size, do real diligence on how achievable each milestone is and who controls it, and you will understand what a deal is genuinely worth, which is a skill that separates sophisticated participants from those who read the press release and stop there.
Get the reversion right
Of all the terms in a licensing agreement, the one most often neglected and most painfully missed is reversion: what happens to your asset if your partner stops developing it. A partner who deprioritizes your program can leave a valuable drug stranded, generating no milestones and reaching no patients, while you have no ability to take it back and no realistic recourse. Negotiate clear diligence obligations and clean reversion rights that return the asset to you if defined progress is not made, because the alternative is watching your best program quietly die inside someone else’s portfolio.
For legal and transactional counsel on these deals, browse the BioMed Nexus legal and IP directory, and see our guides on out-licensing a drug program and building a biotech BD function.
Frequently asked questions
What are biobucks in a biotech deal?
Biobucks is the industry's wry term for the headline value of a licensing deal, which sums the upfront payment plus every possible milestone at its maximum. It assumes the drug clears every clinical hurdle, wins approval, and hits peak commercial milestones, an outcome that is genuinely unlikely, so the headline number is usually far larger than what actually gets paid.
What is the difference between an upfront, a milestone and a royalty?
The upfront is cash paid at signing and is the only certain money. Milestones are contingent payments triggered by specified events, split into development milestones (clinical and regulatory progress) and commercial milestones (sales thresholds). Royalties are a percentage of net sales paid over time, and they are where the truly large value sits if a drug becomes a commercial success.
How should I evaluate a biotech licensing deal?
Look past the headline at the upfront, which is the certain money and the truest signal of conviction; the structure of milestones, since development milestones tied to near-term events are worth far more in expectation than sales milestones requiring blockbuster revenue; the royalty rate and terms; and other terms like territory, retained rights and reversion if the partner stalls.
